These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37682707)

  • 21. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
    Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
    Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
    Wood K; Hensing T; Malik R; Salgia R
    JAMA Oncol; 2016 Jun; 2(6):805-12. PubMed ID: 27100819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
    Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
    J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
    Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substrate docking-mediated specific and efficient lysine methylation by the SET domain-containing histone methyltransferase SETD7.
    Liu H; Li Z; Yang Q; Liu W; Wan J; Li J; Zhang M
    J Biol Chem; 2019 Sep; 294(36):13355-13365. PubMed ID: 31324717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
    Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
    Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
    Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
    Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
    Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does Molecular Profiling of
    Karim NA; Ullah A; Pathrose P; Fathallah H; Perry A; Morris JC; Wang J; Starnes SL
    Curr Oncol; 2022 Jul; 29(7):4779-4790. PubMed ID: 35877239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
    Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
    BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
    Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
    Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS.
    Fan Q; Hu X; Zhang H; Wang S; Zhang H; You C; Zhang CY; Liang H; Chen X; Ba Y
    Cell Physiol Biochem; 2017; 44(4):1311-1324. PubMed ID: 29183007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
    Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Ohm AM; Tan AC; Heasley LE; Reyland ME
    Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular landscape of histone lysine methyltransferases and demethylases in non-small cell lung cancer.
    Li J; Tao X; Shen J; Liu L; Zhao Q; Ma Y; Tao Z; Zhang Y; Ding B; Xiao Z
    Int J Med Sci; 2019; 16(7):922-930. PubMed ID: 31341405
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
    da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.